Vision-FFR trial compares vFFR with optical coherence tomography in chronic coronary syndromes

Every day in catheterization laboratories around the world, cardiologists confront the same frustrating category of blockage: the intermediate coronary stenosis, a narrowing that fills somewhere between 40 and 80 percent of a heart artery’s diameter and that looks, on a routine angiogram, neither clearly harmless nor clearly guilty. For decades, settling such cases has meant threading a pressure-sensitive wire past the lesion and stressing the heart with a vasodilator drug. A study published in the journal Clinical Research in Cardiology points toward a different path. In the prospective VISION-FFR study, a team of Polish cardiologists led by first author Piotr Baruś and senior author Mariusz Tomaniak paired a fully computational measure of coronary flow limitation — vessel fractional flow reserve, or vFFR — with optical coherence tomography, an intravascular imaging technique that resolves coronary plaques at near-microscopic scale. Their question was deceptively simple: can software reproduce the physiologic gold standard, and can microscopic images of the plaque itself explain what that number means?

Fractional flow reserve, or FFR, has been the reference standard for judging the functional significance of a coronary narrowing since the concept was formalized in the early 1990s and hardened through landmark randomized trials. The index is elegantly physical: it expresses the maximum blood flow an artery can deliver through a stenosis as a fraction of the flow the same artery would deliver if the vessel were perfectly open. Because flow during maximal hyperemia is proportional to perfusion pressure, FFR is measured invasively as the mean pressure distal to the narrowing divided by the mean pressure in the aorta, with hyperemia induced by intravenous or intracoronary adenosine. A value of 0.80 or below — meaning the stenosis consumes at least a fifth of the pressure that should be driving the heart muscle’s blood supply — defines a hemodynamically significant lesion. Randomized trials such as FAME and FAME 2 established that guiding stent decisions by this pressure ratio, rather than by the eye, reduces adverse cardiac events and spares patients unnecessary implants, and international guidelines have endorsed the measurement for exactly the kind of intermediate lesions that plague daily practice.

Yet the technique remains underused relative to its evidence base. Crossing the lesion with a dedicated pressure guidewire adds procedural time and cost; adenosine frequently causes flushing, chest burning, breathlessness and transient conduction abnormalities that patients find deeply unpleasant; and the measurement demands technical care, because wire handling, catheter damping and inadequate hyperemia can all distort the result. Meanwhile, decades of comparison studies have shown that visual estimation from angiography is a poor surrogate for physiology: roughly half of angiographically intermediate lesions turn out to be non-flow-limiting when actually measured, and experienced operators frequently disagree with one another about severity. This is the gray zone in which the “oculostenotic reflex” — the reflexive impulse to stent anything that looks tight — flourishes, contributing both to the over-treatment of lesions that would never have caused ischemia and to the occasional under-treatment of those that would. The gap between what the artery looks like and what it does is precisely the gap that computational physiology was invented to close.

Vessel fractional flow reserve belongs to the fast-growing family of angiography-derived, computed FFR indices — cousins of the CT-derived FFR-CT that pioneered the field. The software ingests standard coronary angiograms acquired from at least two projection angles and reconstructs a three-dimensional model of the arterial lumen, quantifying the vessel’s caliber, length and lesion geometry along its full course. Blood flow is then estimated from angiographic frame counts and vessel dimensions, and the pressure drop across the reconstructed geometry is solved numerically with computational fluid dynamics — in most implementations, variants of the Navier–Stokes equations that govern pressure and flow in a tube — accounting for viscous friction losses along diffuse disease and for separation losses at focal narrowings. The output is a hyperemic pressure ratio calculated without a wire, without adenosine and within minutes — and, because the computation is distributed along the entire artery, a pressure profile showing exactly where along the vessel flow is lost, which is the origin of the term “vessel” FFR.

Optical coherence tomography attacks the same stenosis from the opposite direction: it ignores hemodynamics entirely and interrogates the structure of the vessel wall. The technique works like ultrasound with light, using a fiber-optic imaging catheter that emits near-infrared radiation at a wavelength of roughly 1.3 micrometers; because red blood cells scatter light ferociously, blood is transiently flushed from the artery with contrast during the acquisition. Second-generation frequency-domain systems pull back at high speed, generating cross-sectional images with an axial resolution of 10 to 20 micrometers — roughly ten times finer than intravascular ultrasound. At that scale, operators can measure the minimal lumen area, map the arc of lipid-rich plaque, quantify the thickness of its fibrous cap, and identify macrophage infiltration, cholesterol crystals, neovascular microchannels, thrombus and the depth of calcification. Where FFR answers whether a stenosis matters, OCT answers what the stenosis is made of — information that has become indispensable both in assessing vulnerable plaque and in optimizing stent implantation.

VISION-FFR brought the two technologies together in a single-center, prospective, observational design. The researchers enrolled patients with chronic coronary syndromes — the umbrella term for the stable and chronic presentations of coronary artery disease, as opposed to acute heart attacks — whose angiograms showed intermediate stenoses of 40 to 80 percent. Every participant underwent the full workup: wire-based FFR with adenosine, computed vFFR derived from the angiogram, and intracoronary OCT of the target vessel, so that 120 lesions in 106 patients could each be characterized simultaneously in physiological and anatomical terms. Because all three indices were assessed in the same lesions, the design eliminates the lesion-selection drift that plagues comparisons across separate cohorts. A cutoff of 0.80 defined hemodynamic significance for both indices. The cohort split cleanly along that line: sixty-two patients fell into the vFFR-positive group, with a median vFFR of 0.72 (interquartile range 0.70–0.77), while forty-four patients were vFFR-negative, with a median of 0.88 (interquartile range 0.85–0.92) — a separation that was statistically significant and consistent with a real physiological divide between the two populations.

The study’s distinctive ambition lies in what that divide might be made of. The stated objective was to evaluate the association between vFFR and OCT-derived parameters — to test whether computed physiology tracks with plaque anatomy measured at micron resolution, and whether lesions that computationally strangle flow also display the OCT signatures cardiologists associate with obstructive and high-risk morphology, such as small minimal lumen areas, large lipid arcs and thin fibrous caps. Previous efforts to predict wire-based FFR from anatomy alone have delivered mixed results: thresholds based on minimal lumen area measured by intravascular imaging improve on visual estimation but still misclassify a substantial share of lesions, because the functional impact of a narrowing depends not only on its tightest point but also on lesion length, on the abruptness of its entry and exit, on diffuse disease elsewhere in the artery and on the mass of heart muscle it supplies. By capturing the computed pressure field and the microscopic plaque landscape in the same lesions, VISION-FFR assembles precisely the paired dataset needed to probe why some anatomies translate into ischemia while others do not.

The practical stakes are considerable. If computed vFFR proves reliable across larger populations, the pressure wire and the adenosine infusion could be reserved for the minority of cases in which the computation is untrustworthy — poor image quality, heavy calcification, complex bifurcations or left main disease — shortening procedures, cutting costs and sparing patients the drug’s side effects. Because vFFR is derived from angiograms that are acquired anyway, it can even be computed retrospectively on stored images, potentially flagging lesions that deserve formal physiological testing. And in the hybrid workflow the Warsaw team’s design anticipates, OCT and vFFR are natural companions: the imaging catheter is already in the artery, and its micron-scale anatomy can contextualize a pressure number that the wire alone cannot explain — distinguishing, for instance, a focal lipid-rich culprit from diffuse disease producing the same value. The caveats are real, though. The study was single-center and observational, with a moderate sample size and no long-term outcomes; computed indices inherit every artifact of the angiograms they are built from; and OCT, for all its resolution, does not quantify diffuse flow limitation along the artery’s length the way a pullback pressure trace does.

The report lands amid a broader migration of coronary physiology from the catheter to the computer. CT-derived FFR, validated in large multicenter studies more than a decade ago, demonstrated that hemodynamic significance could be simulated noninvasively and even used to defer invasive angiography altogether in stable patients; angiography-derived platforms followed, with validation studies against wire-based FFR showing high agreement, and machine-learning implementations have since compressed computation times from hours to seconds. The economic logic is equally attractive: a computation that runs on images already acquired costs a fraction of a disposable pressure wire, and an index that needs no adenosine removes both the drug’s discomfort and the minutes spent waiting for hyperemia. What VISION-FFR adds is the anatomical cross-examination: rather than asking only whether the computed number agrees with the wire, the Polish team asked what the plaque looks like when the algorithm declares a vessel positive, anchoring the virtual physiology in physical structures that operators can see, measure and — eventually — target.

Larger, multicenter and ideally outcome-driven studies will be needed before computed vessel physiology and OCT-derived morphology can jointly decide who receives a stent and who goes home on medication alone. But the direction of travel is unmistakable. Cardiology has spent a generation learning that the angiogram’s grayscale silhouette is an unreliable narrator of ischemia, and the tools that correct it are becoming faster, cheaper and image-only. If that evidence matures, the catheterization laboratory of the near future could look radically leaner: an angiogram, a computation and, where anatomy demands explanation, a light-based pullback. If subsequent work confirms the Warsaw findings, the intermediate stenosis may finally lose its status as the catheterization laboratory’s most persistent dilemma — adjudicated instead by a digital twin of the coronary circulation, cross-examined by light.